Neupath Health Stock Performance
| NPTH Stock | CAD 0.20 0.02 11.11% |
The company secures a Beta (Market Risk) of 0.3, which conveys not very significant fluctuations relative to the market. As returns on the market increase, NeuPath Health's returns are expected to increase less than the market. However, during the bear market, the loss of holding NeuPath Health is expected to be smaller as well. At this point, NeuPath Health has a negative expected return of -0.0298%. Please make sure to verify NeuPath Health's potential upside, kurtosis, daily balance of power, as well as the relationship between the skewness and accumulation distribution , to decide if NeuPath Health performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days NeuPath Health has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, NeuPath Health is not utilizing all of its potentials. The recent stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
Dividend Date 2020-07-06 |
1 | NeuPath Health brings top osteoarthritis treatment to Canada - MSN | 03/07/2025 |
| Begin Period Cash Flow | 1.5 M |
NeuPath |
NeuPath Health Relative Risk vs. Return Landscape
If you would invest 19.00 in NeuPath Health on December 21, 2024 and sell it today you would lose (1.00) from holding NeuPath Health or give up 5.26% of portfolio value over 90 days. NeuPath Health is producing return of less than zero assuming 3.5132% volatility of returns over the 90 days investment horizon. Simply put, 31% of all stocks have less volatile historical return distribution than NeuPath Health, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
NeuPath Health Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NeuPath Health's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NeuPath Health, and traders can use it to determine the average amount a NeuPath Health's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0085
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NPTH |
Estimated Market Risk
| 3.51 actual daily | 31 69% of assets are more volatile |
Expected Return
| -0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average NeuPath Health is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NeuPath Health by adding NeuPath Health to a well-diversified portfolio.
NeuPath Health Fundamentals Growth
NeuPath Stock prices reflect investors' perceptions of the future prospects and financial health of NeuPath Health, and NeuPath Health fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NeuPath Stock performance.
| Return On Equity | -0.0308 | ||||
| Return On Asset | 0.017 | ||||
| Profit Margin | (0.01) % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 18.67 M | ||||
| Shares Outstanding | 56.4 M | ||||
| Price To Book | 0.47 X | ||||
| Price To Sales | 0.14 X | ||||
| Revenue | 66.1 M | ||||
| Gross Profit | 13.46 M | ||||
| EBITDA | 2.16 M | ||||
| Net Income | (107 K) | ||||
| Cash And Equivalents | 7.48 M | ||||
| Cash Per Share | 0.17 X | ||||
| Total Debt | 195 K | ||||
| Debt To Equity | 0.67 % | ||||
| Book Value Per Share | 0.38 X | ||||
| Cash Flow From Operations | 3.03 M | ||||
| Earnings Per Share | (0.02) X | ||||
| Total Asset | 41.78 M | ||||
| Retained Earnings | (26.02 M) | ||||
About NeuPath Health Performance
Evaluating NeuPath Health's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if NeuPath Health has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NeuPath Health has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
NeuPath Health Inc. provides chronic pain management services in Canada. The company operates 13 clinics under the Centres for Pain Management and InMedic Creative Medicine brands in Ontario and Alberta. NEUPATH HEALTH operates under Medical Care Facilities classification in Exotistan and is traded on Commodity Exchange.Things to note about NeuPath Health performance evaluation
Checking the ongoing alerts about NeuPath Health for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NeuPath Health help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NeuPath Health generated a negative expected return over the last 90 days | |
| NeuPath Health has some characteristics of a very speculative penny stock | |
| NeuPath Health has high historical volatility and very poor performance | |
| The company reported the revenue of 66.1 M. Net Loss for the year was (107 K) with profit before overhead, payroll, taxes, and interest of 13.46 M. | |
| Latest headline from news.google.com: NeuPath Health brings top osteoarthritis treatment to Canada - MSN |
- Analyzing NeuPath Health's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NeuPath Health's stock is overvalued or undervalued compared to its peers.
- Examining NeuPath Health's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NeuPath Health's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NeuPath Health's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NeuPath Health's stock. These opinions can provide insight into NeuPath Health's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for NeuPath Stock Analysis
When running NeuPath Health's price analysis, check to measure NeuPath Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuPath Health is operating at the current time. Most of NeuPath Health's value examination focuses on studying past and present price action to predict the probability of NeuPath Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuPath Health's price. Additionally, you may evaluate how the addition of NeuPath Health to your portfolios can decrease your overall portfolio volatility.